Skip to main content
Caplight Logo









inSoma Bio

inSoma Bio

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://insomabio.com/

Last Round

Accelerator

Jun 5, 2025

Est. Valuation

$1.79M

Total Funding Raised

$10.54M

Company Overview

inSoma Bio is a biotechnology company that develops bioengineered reconstructive biomaterials for plastic and reconstructive surgery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Advanced Materials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biomaterialsreconstructive surgeryprotein engineeringregenerative medicinesoft-tissue reconstructioninjectable scaffoldbiotechmedical devicesrecombinant proteinautologous tissuethermoresponsive materialplastic surgerybio-scaffoldtissue engineeringgood manufacturing practiceGMP

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

inSoma Bio Comparables

Compare inSoma Bio with similar companies based on industry and business-model similarity.

inSoma Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
LifeSprout
83%
Healshape
79%
BellaSeno
79%

inSoma Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorJun 5, 2025
SeedNov 1, 2023
GrantSep 1, 2023
GrantMar 31, 2023
GrantDec 15, 2022
Debt
Dec 15, 2022

inSoma Bio Investors

Notable investors and investment history

inSoma Bio investors
InvestorRounds
National Cancer InstituteGrant
MedTech InnovatorAccelerator
NIH RADxGrant
Makai VCSeed
MedBlue IncubatorSeed
Y CombinatorPre Seed, Accelerator
North Carolina Biotechnology CenterDebt, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors increased 433% MoM.

  • Jun 5, 2025

    Received funding from MedTech Innovator.

inSoma Bio Filings

Explore SEC and related filing metadata, where available.

inSoma Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about inSoma Bio's valuation, stock price, and market status.

Is inSoma Bio a public or private company?

inSoma Bio is a private company.

What is the current stock price of inSoma Bio?

inSoma Bio is a private company with no public stock price. No recent secondary market data is available.

How much is inSoma Bio worth (valuation)?

Valuation information for inSoma Bio is not publicly available.

Can I buy inSoma Bio stock?

inSoma Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was inSoma Bio's last funding round?

inSoma Bio's most recent funding round was Accelerator on June 5, 2025.

Who are the main investors in inSoma Bio?

Key investors in inSoma Bio include National Cancer Institute, MedTech Innovator, NIH RADx, Y Combinator, North Carolina Biotechnology Center.

Will inSoma Bio IPO soon?

No public IPO plans have been announced for inSoma Bio.

How can I track inSoma Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor inSoma Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range10
Year Founded2018
Last FundingJun 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?